Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood
Jung K, Laube C, Lein M, Lichtinghagen R, Tschesche H, Schnorr D, Loening SA (1998)
CLINICAL CHEMISTRY 44(5): 1060-1062.
Zeitschriftenaufsatz
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Jung, K;
Laube, C;
Lein, M;
Lichtinghagen, R;
Tschesche, HaraldUniBi;
Schnorr, D;
Loening, SA
Einrichtung
Erscheinungsjahr
1998
Zeitschriftentitel
CLINICAL CHEMISTRY
Band
44
Ausgabe
5
Seite(n)
1060-1062
ISSN
0009-9147
Page URI
https://pub.uni-bielefeld.de/record/1625636
Zitieren
Jung K, Laube C, Lein M, et al. Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. CLINICAL CHEMISTRY. 1998;44(5):1060-1062.
Jung, K., Laube, C., Lein, M., Lichtinghagen, R., Tschesche, H., Schnorr, D., & Loening, S. A. (1998). Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. CLINICAL CHEMISTRY, 44(5), 1060-1062.
Jung, K, Laube, C, Lein, M, Lichtinghagen, R, Tschesche, Harald, Schnorr, D, and Loening, SA. 1998. “Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood”. CLINICAL CHEMISTRY 44 (5): 1060-1062.
Jung, K., Laube, C., Lein, M., Lichtinghagen, R., Tschesche, H., Schnorr, D., and Loening, S. A. (1998). Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. CLINICAL CHEMISTRY 44, 1060-1062.
Jung, K., et al., 1998. Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. CLINICAL CHEMISTRY, 44(5), p 1060-1062.
K. Jung, et al., “Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood”, CLINICAL CHEMISTRY, vol. 44, 1998, pp. 1060-1062.
Jung, K., Laube, C., Lein, M., Lichtinghagen, R., Tschesche, H., Schnorr, D., Loening, S.A.: Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. CLINICAL CHEMISTRY. 44, 1060-1062 (1998).
Jung, K, Laube, C, Lein, M, Lichtinghagen, R, Tschesche, Harald, Schnorr, D, and Loening, SA. “Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood”. CLINICAL CHEMISTRY 44.5 (1998): 1060-1062.
54 Zitationen in Europe PMC
Daten bereitgestellt von Europe PubMed Central.
Matrix Metalloproteinases and Subclinical Atherosclerosis in Chronic Kidney Disease: A Systematic Review.
Kousios A, Kouis P, Panayiotou AG., Int J Nephrol 2016(), 2016
PMID: 27042350
Kousios A, Kouis P, Panayiotou AG., Int J Nephrol 2016(), 2016
PMID: 27042350
Reference intervals of plasma matrix metalloproteinases 2, 3, and 9 and serum asymmetric dimethylarginine levels.
Kusnierova P, Vsiansky F, Pleva L, Plevova P, Safarcik K, Svagera Z., Scand J Clin Lab Invest 75(6), 2015
PMID: 26151887
Kusnierova P, Vsiansky F, Pleva L, Plevova P, Safarcik K, Svagera Z., Scand J Clin Lab Invest 75(6), 2015
PMID: 26151887
Plasma Matrix Metalloproteinase-9 Levels Predict First-Time Coronary Heart Disease: An 8-Year Follow-Up of a Community-Based Middle Aged Population.
Garvin P, Jonasson L, Nilsson L, Falk M, Kristenson M., PLoS One 10(9), 2015
PMID: 26389803
Garvin P, Jonasson L, Nilsson L, Falk M, Kristenson M., PLoS One 10(9), 2015
PMID: 26389803
Reappraisal of quantitative gel zymography for matrix metalloproteinases.
Prescimone T, Tognotti D, Caselli C, Cabiati M, D'Amico A, Del Ry S, Giannessi D., J Clin Lab Anal 28(5), 2014
PMID: 24648291
Prescimone T, Tognotti D, Caselli C, Cabiati M, D'Amico A, Del Ry S, Giannessi D., J Clin Lab Anal 28(5), 2014
PMID: 24648291
Heparin administration leads to rapid decrease in plasma matrix metalloproteinase-9.
Lee R, Adlam D, Antoniades C, Digby JE, Kharbanda RK, Choudhury RP, Channon KM., Int J Cardiol 163(2), 2013
PMID: 22805545
Lee R, Adlam D, Antoniades C, Digby JE, Kharbanda RK, Choudhury RP, Channon KM., Int J Cardiol 163(2), 2013
PMID: 22805545
Utility of plasma matrix metalloproteinase-9 as a possible diagnostic marker of endoleak post endovascular aneurysm repair.
Lee R, Handa AI., Eur J Vasc Endovasc Surg 43(5), 2012
PMID: 22386381
Lee R, Handa AI., Eur J Vasc Endovasc Surg 43(5), 2012
PMID: 22386381
Gastric cancer - The role of matrix metalloproteinases in tumor progression.
Lukaszewicz-Zając M, Mroczko B, Szmitkowski M., Clin Chim Acta 412(19-20), 2011
PMID: 21693112
Lukaszewicz-Zając M, Mroczko B, Szmitkowski M., Clin Chim Acta 412(19-20), 2011
PMID: 21693112
Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer.
Roy R, Yang J, Moses MA., J Clin Oncol 27(31), 2009
PMID: 19738110
Roy R, Yang J, Moses MA., J Clin Oncol 27(31), 2009
PMID: 19738110
Plasma and serum levels of tissue inhibitor of metalloproteinases-1 are associated with prognosis in node-negative breast cancer: a prospective study.
Würtz SØ, Møller S, Mouridsen H, Hertel PB, Friis E, Brünner N., Mol Cell Proteomics 7(2), 2008
PMID: 17998244
Würtz SØ, Møller S, Mouridsen H, Hertel PB, Friis E, Brünner N., Mol Cell Proteomics 7(2), 2008
PMID: 17998244
Differences in both matrix metalloproteinase 9 concentration and zymographic profile between plasma and serum with clot activators are due to the presence of amorphous silica or silicate salts in blood collection devices.
Mannello F, Tanus-Santos JE, Meschiari CA, Tonti GA., Anal Biochem 374(1), 2008
PMID: 18082127
Mannello F, Tanus-Santos JE, Meschiari CA, Tonti GA., Anal Biochem 374(1), 2008
PMID: 18082127
Matrix metalloproteinase-8 and tissue inhibitor of metalloproteinase-1 in serum do not reflect the analytes circulating in blood.
Jung K., Arterioscler Thromb Vasc Biol 28(3), 2008
PMID: 18048765
Jung K., Arterioscler Thromb Vasc Biol 28(3), 2008
PMID: 18048765
Functional polymorphisms in the promoter of the matrix metalloproteinase-9 (MMP-9) gene are not linked with significant plasma MMP-9 variations in healthy subjects.
Demacq C, Vasconcellos VB, Marcaccini AM, Gerlach RF, Silva WA, Tanus-Santos JE., Clin Chem Lab Med 46(1), 2008
PMID: 18194081
Demacq C, Vasconcellos VB, Marcaccini AM, Gerlach RF, Silva WA, Tanus-Santos JE., Clin Chem Lab Med 46(1), 2008
PMID: 18194081
Preanalytical factors affecting the stability of matrix metalloproteinase-2 concentrations in cerebrospinal fluid.
Sulik A, Wojtkowska M, Oldak E., Clin Chim Acta 392(1-2), 2008
PMID: 18373981
Sulik A, Wojtkowska M, Oldak E., Clin Chim Acta 392(1-2), 2008
PMID: 18373981
A strong note of caution in using matrix metalloproteinase-1 and its inhibitor, TIMP-1 in serum as biomarkers in systolic heart failure.
Jung K., J Intern Med 264(3), 2008
PMID: 18341527
Jung K., J Intern Med 264(3), 2008
PMID: 18341527
Influence of blood sampling procedure on plasma concentrations of matrix metalloproteinases and their tissue inhibitors.
Rossignol P, Cambillau M, Bissery A, Mouradian D, Benetos A, Michel JB, Plouin PF, Chatellier G, Jacob MP., Clin Exp Pharmacol Physiol 35(4), 2008
PMID: 18307742
Rossignol P, Cambillau M, Bissery A, Mouradian D, Benetos A, Michel JB, Plouin PF, Chatellier G, Jacob MP., Clin Exp Pharmacol Physiol 35(4), 2008
PMID: 18307742
Serum or plasma samples? The "Cinderella" role of blood collection procedures: preanalytical methodological issues influence the release and activity of circulating matrix metalloproteinases and their tissue inhibitors, hampering diagnostic trueness and leading to misinterpretation.
Mannello F., Arterioscler Thromb Vasc Biol 28(4), 2008
PMID: 18354094
Mannello F., Arterioscler Thromb Vasc Biol 28(4), 2008
PMID: 18354094
Inverse relationship between markers of nitric oxide formation and plasma matrix metalloproteinase-9 levels in healthy volunteers.
Demacq C, Metzger IF, Gerlach RF, Tanus-Santos JE., Clin Chim Acta 394(1-2), 2008
PMID: 18455513
Demacq C, Metzger IF, Gerlach RF, Tanus-Santos JE., Clin Chim Acta 394(1-2), 2008
PMID: 18455513
Serum samples are inappropriate for use in measuring circulating matrix metalloproteinases: comment on the article by Young-Min et al.
Jung K., Arthritis Rheum 58(5), 2008
PMID: 18438823
Jung K., Arthritis Rheum 58(5), 2008
PMID: 18438823
Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood.
Mannello F, Jung K, Tonti GA, Canestrari F., Clin Biochem 41(18), 2008
PMID: 18926810
Mannello F, Jung K, Tonti GA, Canestrari F., Clin Biochem 41(18), 2008
PMID: 18926810
Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma.
Gerlach RF, Demacq C, Jung K, Tanus-Santos JE., Clin Biochem 40(1-2), 2007
PMID: 17150202
Gerlach RF, Demacq C, Jung K, Tanus-Santos JE., Clin Biochem 40(1-2), 2007
PMID: 17150202
The role of ethylenediamine tetraacetic acid (EDTA) as in vitro anticoagulant for diagnostic purposes.
Banfi G, Salvagno GL, Lippi G., Clin Chem Lab Med 45(5), 2007
PMID: 17484616
Banfi G, Salvagno GL, Lippi G., Clin Chem Lab Med 45(5), 2007
PMID: 17484616
Matrix metalloprotease-2 and -9 concentration and activity in serum and culture medium samples: a methodological reappraisal.
Colotti C, Angeli V, Del Ry S, Maltinti M, Vittorini S, Giannessi D., Clin Chem Lab Med 45(10), 2007
PMID: 17727309
Colotti C, Angeli V, Del Ry S, Maltinti M, Vittorini S, Giannessi D., Clin Chem Lab Med 45(10), 2007
PMID: 17727309
The 'never-ending story' of the influence of blood specimen collection methods affecting the concentration, the zymographic profile and the usefulness of matrix metalloproteinases and their tissue inhibitors in multiple sclerosis diagnosis/prognosis: a landmark for limiting the misuse of serum samples.
Mannello F, Tonti GA, Canestrari F., Mult Scler 13(5), 2007
PMID: 17548455
Mannello F, Tonti GA, Canestrari F., Mult Scler 13(5), 2007
PMID: 17548455
The Sample Type used Affects the Levels of Gelatinases (MMP-2 and -9) and their Inhibitors (TIMP-1 and -2) in Circulating Blood of Healthy Controls and Breast Cancer Patients.
Paula K, Anne TM, Taina TH., Biomark Insights 2(), 2007
PMID: 19662197
Paula K, Anne TM, Taina TH., Biomark Insights 2(), 2007
PMID: 19662197
Gelatinase concentrations and zymographic profiles in human breast cancer: matrix metalloproteinases circulating in plasma are better markers for the subclassification and early prediction of cancer: the coagulation/fibrinolysis pathways alter the release, activation and recovery of different gelatinases in serum.
Mannello F, Tonti GA., Int J Cancer 121(1), 2007
PMID: 17315186
Mannello F, Tonti GA., Int J Cancer 121(1), 2007
PMID: 17315186
Cancer biomarker discovery via low molecular weight serum proteome profiling - Where is the tumor?.
Davis MT, Auger P, Spahr C, Patterson SD., Proteomics - Clinical Applications 1(12), 2007
PMID: C1686
Davis MT, Auger P, Spahr C, Patterson SD., Proteomics - Clinical Applications 1(12), 2007
PMID: C1686
Sample processing and its preanalytical impact on the measurement of circulating matrix metalloproteinases.
Jung K., Clin Chem Lab Med 44(4), 2006
PMID: 16599848
Jung K., Clin Chem Lab Med 44(4), 2006
PMID: 16599848
Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in multiple sclerosis.
Gerlach RF, Tanus-Santos JE., Clin Neurol Neurosurg 108(6), 2006
PMID: 16413675
Gerlach RF, Tanus-Santos JE., Clin Neurol Neurosurg 108(6), 2006
PMID: 16413675
Serum samples should not be used to assess circulating matrix metalloproteinase-9 levels as a prognostic marker of disease.
Tanus-Santos JE, Gerlach RF., Int J Cancer 118(3), 2006
PMID: 16094623
Tanus-Santos JE, Gerlach RF., Int J Cancer 118(3), 2006
PMID: 16094623
Misuse of serum matrix metalloproteinase (MMP)-9 and tissue inhibitor of metalloproteinase (TIMP)-1 as a biomarker in multiple sclerosis.
Gerlach RF, Tanus-Santos JE., Mult Scler 12(1), 2006
PMID: 16459731
Gerlach RF, Tanus-Santos JE., Mult Scler 12(1), 2006
PMID: 16459731
Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196.
Zucker S, Wang M, Sparano JA, Gradishar WJ, Ingle JN, Davidson NE, Eastern Cooperative Oncology Group., Clin Breast Cancer 6(6), 2006
PMID: 16595036
Zucker S, Wang M, Sparano JA, Gradishar WJ, Ingle JN, Davidson NE, Eastern Cooperative Oncology Group., Clin Breast Cancer 6(6), 2006
PMID: 16595036
Preanalytical pitfalls of blood sampling to measure true circulating matrix metalloproteinase 9 and tissue inhibitors of matrix metalloproteinases.
Jung K, Gerlach RF, Tanus-Santos JE., Clin Chim Acta 373(1-2), 2006
PMID: 16616058
Jung K, Gerlach RF, Tanus-Santos JE., Clin Chim Acta 373(1-2), 2006
PMID: 16616058
Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in congestive heart failure.
Gerlach RF, Tanus-Santos JE., Am Heart J 152(1), 2006
PMID: 16824824
Gerlach RF, Tanus-Santos JE., Am Heart J 152(1), 2006
PMID: 16824824
Low serum level of pro-matrix metalloproteinase 2 correlates with aggressive behavior in breast carcinoma.
Kuvaja P, Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T., Hum Pathol 37(10), 2006
PMID: 16949931
Kuvaja P, Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T., Hum Pathol 37(10), 2006
PMID: 16949931
Plasma storage at -80 degrees C does not protect matrix metalloproteinase-9 from degradation.
Rouy D, Ernens I, Jeanty C, Wagner DR., Anal Biochem 338(2), 2005
PMID: 15745750
Rouy D, Ernens I, Jeanty C, Wagner DR., Anal Biochem 338(2), 2005
PMID: 15745750
Consideration of preanalytical conditions to use circulating matrix metalloproteinases as diagnostic markers.
Jung K., Transplantation 79(6), 2005
PMID: 15785392
Jung K., Transplantation 79(6), 2005
PMID: 15785392
Preanalytical conditions and circulating matrix metalloproteinases.
Verspaget HW, Kuyvenhoven JP, van Hoek B., Transplantation 79(6), 2005
PMID: 15785393
Verspaget HW, Kuyvenhoven JP, van Hoek B., Transplantation 79(6), 2005
PMID: 15785393
Serum or plasma: what kind of blood sample should be used to measure circulating matrix metalloproteinases and their inhibitors?
Jung K., J Neuroimmunol 162(1-2), 2005
PMID: 15833353
Jung K., J Neuroimmunol 162(1-2), 2005
PMID: 15833353
Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease.
Zeng B, Prasan A, Fung KC, Solanki V, Bruce D, Freedman SB, Brieger D., Intern Med J 35(6), 2005
PMID: 15892761
Zeng B, Prasan A, Fung KC, Solanki V, Bruce D, Freedman SB, Brieger D., Intern Med J 35(6), 2005
PMID: 15892761
Circulating matrix metalloproteinase-9 levels as a possible marker of aortic stiffness.
Tanus-Santos JE, Gerlach RF., Arterioscler Thromb Vasc Biol 25(8), 2005
PMID: 16055752
Tanus-Santos JE, Gerlach RF., Arterioscler Thromb Vasc Biol 25(8), 2005
PMID: 16055752
Blood sampling as critical preanalytical determinant to use circulating MMP and TIMP as surrogate markers for pathological processes.
Jung K, Meisser A, Bischof P., Int J Cancer 116(6), 2005
PMID: 15856460
Jung K, Meisser A, Bischof P., Int J Cancer 116(6), 2005
PMID: 15856460
Prognostic value of serum vascular endothelial growth factor (VEGF) and plasma activity of matrix metalloproteinase (MMP) 2 and 9 in lymphoma-affected dogs.
Gentilini F, Calzolari C, Turba ME, Agnoli C, Fava D, Forni M, Bergamini PF., Leuk Res 29(11), 2005
PMID: 15893373
Gentilini F, Calzolari C, Turba ME, Agnoli C, Fava D, Forni M, Bergamini PF., Leuk Res 29(11), 2005
PMID: 15893373
Expression and activity of matrix metalloproteinases-2 and -9 in serum, core needle biopsies and tissue specimens of prostate cancer patients.
Sauer CG, Kappeler A, Späth M, Kaden JJ, Michel MS, Mayer D, Bleyl U, Grobholz R., Virchows Arch 444(6), 2004
PMID: 15088144
Sauer CG, Kappeler A, Späth M, Kaden JJ, Michel MS, Mayer D, Bleyl U, Grobholz R., Virchows Arch 444(6), 2004
PMID: 15088144
Use of citrate to minimize neutrophil matrix metalloproteinase-9 in human plasma.
Makowski GS, Ramsby ML., Anal Biochem 322(2), 2003
PMID: 14596841
Makowski GS, Ramsby ML., Anal Biochem 322(2), 2003
PMID: 14596841
Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C.
Boeker KH, Haberkorn CI, Michels D, Flemming P, Manns MP, Lichtinghagen R., Clin Chim Acta 316(1-2), 2002
PMID: 11750276
Boeker KH, Haberkorn CI, Michels D, Flemming P, Manns MP, Lichtinghagen R., Clin Chim Acta 316(1-2), 2002
PMID: 11750276
Re: Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer (Respir Med 2001; 95: 1-4).
John M, Oltmanns U, Witt C, Jung K., Respir Med 96(2), 2002
PMID: 11860170
John M, Oltmanns U, Witt C, Jung K., Respir Med 96(2), 2002
PMID: 11860170
Preanalytical aspects regarding the measurement of metalloproteinase-9 and tissue inhibitor or metalloproteinase-1 in blood.
Alby C, Ben Abdesselam O, Foglietti MJ, Beaudeux JL., Clin Chim Acta 325(1-2), 2002
PMID: 12367785
Alby C, Ben Abdesselam O, Foglietti MJ, Beaudeux JL., Clin Chim Acta 325(1-2), 2002
PMID: 12367785
Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis.
Noji Y, Kajinami K, Kawashiri MA, Todo Y, Horita T, Nohara A, Higashikata T, Inazu A, Koizumi J, Takegoshi T, Mabuchi H., Clin Chem Lab Med 39(5), 2001
PMID: 11434385
Noji Y, Kajinami K, Kawashiri MA, Todo Y, Horita T, Nohara A, Higashikata T, Inazu A, Koizumi J, Takegoshi T, Mabuchi H., Clin Chem Lab Med 39(5), 2001
PMID: 11434385
Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood.
Jung K, Lein M, Laube C, Lichtinghagen R., Clin Chim Acta 314(1-2), 2001
PMID: 11718702
Jung K, Lein M, Laube C, Lichtinghagen R., Clin Chim Acta 314(1-2), 2001
PMID: 11718702
Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma.
Lein M, Jung K, Laube C, Hübner T, Winkelmann B, Stephan C, Hauptmann S, Rudolph B, Schnorr D, Loening SA., Int J Cancer 85(6), 2000
PMID: 10709099
Lein M, Jung K, Laube C, Hübner T, Winkelmann B, Stephan C, Hauptmann S, Rudolph B, Schnorr D, Loening SA., Int J Cancer 85(6), 2000
PMID: 10709099
MMP-9 activity in urine from patients with various tumors, as measured by a novel MMP activity assay using modified urokinase as a substrate.
Hanemaaijer R, Sier CF, Visser H, Scholte L, van Lent N, Toet K, Hoekman K, Verheijen JH., Ann N Y Acad Sci 878(), 1999
PMID: 10415726
Hanemaaijer R, Sier CF, Visser H, Scholte L, van Lent N, Toet K, Hoekman K, Verheijen JH., Ann N Y Acad Sci 878(), 1999
PMID: 10415726
Matrix metalloproteinase-2 in blood does not indicate the progression of prostate cancer.
Jung K, Laube C, Lein M, Türk I, Lichtinghagen R, Rudolph B, Schnorr D, Loening SA., Int J Cancer 78(3), 1998
PMID: 9766579
Jung K, Laube C, Lein M, Türk I, Lichtinghagen R, Rudolph B, Schnorr D, Loening SA., Int J Cancer 78(3), 1998
PMID: 9766579
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Quellen
PMID: 9590387
PubMed | Europe PMC
Suchen in
Google Scholar